Description: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Home Page: www.delcath.com
DCTH Technical Analysis
1633 Broadway
New York,
NY
10019
United States
Phone:
212 489 2100
Officers
| Name | Title |
|---|---|
| Mr. Gerard J. Michel MBA, MS | CEO & Director |
| Mr. John Purpura M.S. | Chief Operating Officer |
| Dr. Johnny John M.D. | Sr. VP Clinical Devel. & Medical Affairs |
| Mr. Anthony C. Dias | VP of Fin. |
| Mr. David Hoffman | Gen. Counsel, Corp. Sec. & Chief Compliance Officer |
| Mr. Robin Wagge | Sr. VP of Rubenstein Associates |
| Mr. Kevin Muir | VP of Commercial Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.0098 |
| Price-to-Sales TTM: | 7.3084 |
| IPO Date: | 2018-05-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |